Axxess Pharma, Inc. Provides Update Regarding Mina Mar Marketing Group
12 August 2010 - 10:00PM
Marketwired
Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company
specializing in the marketing and distribution of both prescription
and non-prescription drugs, announces on June 14, 2010 Taylor
Capitol, Inc was hired as Investor Relations to replace Mina Mar
Marketing Group. It is Axxess Pharma's belief that Mina Mar was not
fulfilling their obligations as Investor Relations and was then
replaced.
Since being replaced, it has come to the attention of Axxess
Pharma that Mina Mar Marketing Group began retaliating against AXXE
for a failed relationship that never materialized. Management
believes based on negative postings, Mina Mar is endeavoring to
damage both the integrity of AXXE and its shareholders. Axxess
Pharma is now initiating action to recover damages by or related to
Mina Mar Marketing Group.
"Despite the negative connotations by Mina Mar, sales for
quarter ending March 31, 2010 increased to $548,000. We remain on
track to increase our fiscal year end 2010 sales by 75 percent.
This growth will be attributed to our current and growing line of
Health Canada approved and soon to be FDA approved prescription and
non-prescription drugs. In the coming press releases we will
provide more detail of the sales generation of our current and
future product lines," stated Gerald Sequeira, President/CEO.
For more information, please contact Investor Relations at (973)
351-3868.
About Axxess Pharma, Inc.:
Axxess Pharma, Inc. is a specialty pharmaceutical company that
focuses on the marketing of dermatological, therapeutic
nutritionals, pain management and diagnostic products in Canada and
abroad since 1997. Axxess owns 22 established pharmaceutical
prescription products that have proven sales in Canada and
internationally. The company has an experienced management team and
field sales force to market products nationally to hospitals and
retail pharmacies as well as specialized practice areas including
Dermatology and Nephrology, Neurology and Urology.
Safe Harbor
Statements about the Company's future expectations and all other
statements in this press release other than historical facts, are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Securities
Litigation Reform Act of 1995. The Company intends that such
forward-looking statements be subject to the safe harbors created
thereby.
The above information contains information relating to the
Company that is based on the beliefs of the Company and/or its
management, as well as assumptions made by any information
currently available to the Company or its management. When used in
this document, the words "anticipate," "estimate," "expect,"
"intend," "plans," "projects," and similar expressions, as they
relate to the Company or its management, are intended to identify
forward-looking statements. Such statements reflect the current
view of the Company regarding future events and are subject to
certain risks, uncertainties and assumptions, including the risks
and uncertainties noted. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
to be incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated, expected,
intended or projected. In each instance, forward-looking
information should be considered in light of the accompanying
meaningful cautionary statements herein. Factors that could cause
results to differ include, but are not limited to, successful
performance of internal plans, the impact of competitive services
and pricing and general economic risks and uncertainties.
Contact: Taylor Capitol, Inc. Investor Relations Stephen Taylor
973-351-3868 Info@TheStockAlerts.com www.TheStockAlerts.com
Allstar Health Brands (PK) (USOTC:ALST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allstar Health Brands (PK) (USOTC:ALST)
Historical Stock Chart
From Jul 2023 to Jul 2024